Royalty Pharma has demonstrated a consistent pattern of delivering earnings above analyst expectations across four straight quarters, but negative price momentum and a risk/reward profile tilted against new buyers suggest the stock's near-term opportunity has narrowed significantly.
Thesis pillars
- Consistent Earnings Beat Streak→Stable
- Piotroski Financial Strength→Stable
- Analyst Sentiment And Coverage→Stable
- +1 more pillar — see the Why tab for full reasoning
Royalty Pharma plc (RPRX) Stock Analysis
Breakout setup
Healthcare · Biotechnology
Sell if holding. Analyst target reached at $57.77 — A.R:R is negative (-0.9) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Near 52-week high (0.1% away).
Royalty Pharma acquires biopharmaceutical royalties, collecting payments based on top-line sales of more than 35 marketed therapies including Vertex's cystic fibrosis franchise, GSK's Trelegy, and Biogen's Tysabri. The company generated $3.3 billion in Portfolio Receipts in... Read more
Sell if holding. Analyst target reached at $57.77 — A.R:R is negative (-0.9) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Near 52-week high (0.1% away). Chart setup: Golden cross, above all MAs, RSI 60, MACD bullish. Score 5.4/10, moderate confidence.
Passes 6/7 gates (positive momentum, clean insider activity, no SEC red flags, earnings proximity 33d clear, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio. Suitability: speculative.
About Royalty Pharma plc
About Royalty Pharma plc
Royalty Pharma generated $3.3 billion in Portfolio Receipts in 2025 — consisting of $3,127 million in Royalty Receipts plus $128 million in milestones — across royalties on more than 35 commercialized biopharmaceutical therapies. The company's largest royalty, on Vertex's cystic fibrosis franchise, produced $917 million in 2025 Portfolio Receipts; 16 therapies in the portfolio each generated end-market sales exceeding $1 billion in 2025, including seven with end-market sales above $3 billion. Royalty Pharma deployed $2.6 billion in capital in 2025 to acquire additional royalties and milestones.
Royalty Pharma earns income as biopharmaceutical companies sell products on which it holds contractual royalty rights, structured as a percentage of top-line net sales ranging from low-single-digit rates to tiered mid-teen rates depending on volume thresholds. Royalties are collected from marketers including Vertex, GSK (Trelegy, $332 million in 2025 Portfolio Receipts), Biogen (Tysabri and Spinraza), Roche (Evrysdi), Pfizer and Astellas (Xtandi), and Johnson and Johnson (Tremfya and Erleada). The company bears no manufacturing, R&D, or commercial costs for these therapies. Portfolio growth comes from deploying capital to acquire new royalties — the company estimates a 48% market share of all biopharmaceutical royalty transactions by value from 2020 through 2025, versus approximately 14% for its nearest competitor. As of December 31, 2025, total outstanding principal on senior unsecured notes and term loans was $9.2 billion, with up to $1.8 billion in revolving credit available.
Show full overview
The cystic fibrosis franchise carries a material contractual dispute: Royalty Pharma believes deuterated ivacaftor (deutivacaftor) in Alyftrek is royalty-bearing, yielding a blended royalty of approximately 8%; Vertex has publicly stated it believes deutivacaftor is not royalty-bearing, yielding a blended royalty of approximately 4% on Alyftrek. Patent applications covering Trikafta are expected to provide exclusivity through 2037, with the franchise overall estimated through 2039-2041 — meaning the single largest Portfolio Receipts contributor faces both potential contractual revenue shortfall and structural decline over the following decade if generics enter.
See also: Healthcare · Biotechnology
From Royalty Pharma plc's most recent 10-K filing, extracted June 11, 2026.
Recent developments
updated 2026-07-06Recent Developments — Royalty Pharma plc
Latest news
- NEWS Royalty Pharma (RPRX) to Release Earnings on Wednesday - MarketBeat — MarketBeat neutral
- NEWS Royalty Pharma (RPRX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release - Yahoo Finance — Yahoo Finance positive
- NEWS Royalty Pharma (NASDAQ:RPRX) Reaches New 1-Year High - Should You Buy? - MarketBeat — MarketBeat positive
- NEWS Royalty Pharma (NASDAQ:RPRX) Hits New 52-Week High - Still a Buy? - MarketBeat — MarketBeat positive
- NEWS Royalty Pharma (RPRX) Reports Q1: Everything You Need To Know Ahead Of Earnings - TradingView — TradingView positive
Generated 2026-07-06T04:40:27Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- MEDIUMProductVertex cystic fibrosis franchise10-K Item 1: 'Our largest marketed royalty in 2025 was on Vertex's cystic fibrosis franchise'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
1 floor-breaker
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Analyst target reached at $57.77 — A.R:R is negative (-0.9) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Near 52-week high (0.1% away). Chart setup: Golden cross, above all MAs, RSI 60, MACD bullish. Prior stop was $54.77. Score 5.4/10, moderate confidence.
Take-profit target: $56.64 (-2.0% upside). Prior stop was $54.77. Stop-loss: $54.77.
Analyst target reached - limited upside remaining; Near 52-week high (0.1% away); Value-trap signals (2/5): Material insider selling (9 sells, 0.05% of cap), Negative free cash flow.
Royalty Pharma plc trades at a P/E of 30.4 (forward 10.3). TrendMatrix value score: 4.4/10. Verdict: Sell.
16 analysts cover RPRX with a consensus score of 4.2/5. Average price target: $59.
What does Royalty Pharma plc do?Royalty Pharma acquires biopharmaceutical royalties, collecting payments based on top-line sales of more than 35...
Royalty Pharma acquires biopharmaceutical royalties, collecting payments based on top-line sales of more than 35 marketed therapies including Vertex's cystic fibrosis franchise, GSK's Trelegy, and Biogen's Tysabri. The company generated $3.3 billion in Portfolio Receipts in 2025, deploying $2.6 billion to acquire new royalties.